Leveraging the expertise of an established multidisciplinary Stanford global cancer team, we propose to test a novel potentially “leapfrog” molecular technology for the determination of ER/PR and Her2 status of breast tumors based on a minimally invasive, fine needle aspiration sample and to compare the accuracy of this approach to the existing “gold standards” of immunohistochemistry (ER/PR) and in situ hybridization (Her2). We feel particularly well equipped to address these challenges as we will be leveraging a multi-stakeholder partnership already in place with industry, the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI) and two comprehensive cancer centers in Nigeria, Ahmadu Bello University Teaching Hospital (ABUTH) and Lagos University Teaching Hospital (LUTH), where these technologies will be tested under the auspices of a collaboratively-designed mentor/partner program with the Stanford team.